New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
06:06 EDTIMUCImmunoCellular granted orphan drug designation for ICT-107 by EMA
ImmunoCellular Therapeutics announced that the European Medicines Agency, or EMA, has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular has previously received orphan designation for ICT-107 in glioblastoma in the US.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
16:23 EDTIMUCImmunoCellular to hold a conference call on ICT-107
Subscribe for More Information
November 20, 2015
06:05 EDTIMUCImmunoCellular presents updated ICT-107 Phase 2 immune response data
ImmunoCellular Therapeutics announced the presentation of recently updated overall survival, or OS, results and immune response data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma. ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. The data are being presented at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, being held in San Antonio, TX. The data from the phase 2 trial continue to indicate a survival advantage in the ICT-107 treated group compared to the control group. The data also show a significant association between immune response and survival, especially in HLA-A2 positive, or HLA-A2+, patients, which is the target patient population for the phase 3 registration trial.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use